Inductive Bio Raises $25M to Expand AI Platform for Fast Track Drug Discovery

Inductive Bio, a New York based biotechnology startup, has raised $25 million in its Series A funding round to advance its AI powered platform for small molecule drug discovery.

The round was led by top investors, including Obvious Ventures, Andreessen Horowitz (a16z) Bio + Health, and Lux Capital.

Inductive Bio’s AI Platform for Drug Discovery Gets $25M in Series A Funding

The funding will be used to expand the company’s AI model development, grow its collaborative data network, and roll out its state of the art technology across the pharmaceutical industry.

Inductive Bio’s Compass platform utilizes machine learning to predict crucial drug properties such as absorption, metabolism, and toxicity prior to synthesis, enabling faster and more efficient compound optimization.

The company’s technology has already been applied to over one million molecule designs and contributed to numerous successful drug discovery initiatives.

Inductive Bio aims to democratize access to advanced AI models, accelerating the development of new therapies and advancing precision medicine.

Founded by Josh Haimson and Ben Birnbaum, former executives at Flatiron Health, Inductive Bio is well positioned to transform the drug discovery process and support the development of life saving treatments.

With this new round of funding, Inductive Bio plans to scale its platform, further driving innovation in AI driven biotechnology.

Kaynak: https://www.inductive.bio/news/inductive-bio-raises-25m-series-a